| Literature DB >> 35388494 |
Weijun Yu1,2, Qisheng Gu3,4, Di Wu5,6, Weiqi Zhang1, Gang Li7, Lu Lin1, Jared M Lowe8, Shucheng Hu1, Tia Wenjun Li5,9, Zhen Zhou10, Michael Z Miao5, Yuhua Gong1, Yifei Zhao1, Eryi Lu1,2.
Abstract
BACKGROUND ANDEntities:
Keywords: bioinformatics analysis; circRNA; circRNA-disease association; high-throughput sequencing; periodontitis
Mesh:
Substances:
Year: 2022 PMID: 35388494 PMCID: PMC9325354 DOI: 10.1111/jre.12989
Source DB: PubMed Journal: J Periodontal Res ISSN: 0022-3484 Impact factor: 3.946
FIGURE 1Analysis of differentially expressed circRNAs in human gingival tissues from patients with or without periodontitis. (A) Workflow of circRNA expression profiling and analysis in human periodontitis. (B) The number of the shared circRNAs and differentially expressed circRNAs. There are 1236 circRNA shared, 1700 circRNA expressed in healthy gingival tissues, and 3116 circRNA expressed in gingival tissues of periodontitis. (C) Heatmap of circRNA expression for gingival tissues from periodontitis patients when compared to periodontal healthy ones. Hierarchical clustering indicates differences in circRNA expression profiling between the two groups. The golden color indicates the upregulated expression and purple color for the downregulated expression. (D) Scatter plot displaying the changes in circRNA expression. The red scatters indicate the upregulated circRNAs, and the blue scatters indicate the downregulated circRNAs with more than a 2.0‐fold change between the two compared groups. The gray scatters indicate otherwise. (E) Volcano plot showing the expression profiling between the two compared groups. The vertical gray lines refer to a 2.0‐fold upregulation and downregulation, respectively. The horizontal gray line corresponds to a p value of .05 (−log10 scaled). The red points in the plot represent the significantly upregulated circRNAs, and the blue points represent the significantly downregulated circRNAs. The most significantly dysregulated circRNAs were highlighted in the figure
Demographic and clinical characteristics of the group of periodontal healthy and the group of periodontitis for high‐throughput sequencing
| Characteristics | Healthy ( | Periodontitis ( |
|---|---|---|
| Age range (years) | 20–29 | 25–37 |
| Age (years) | 24.83 ± 3.31 | 31.33 ± 5.13* |
| Gender (male/female) | 2/4 | 3/3 |
| BMI (kg/m2) | 19.84 ± 1.11 | 20.39 ± 2.71 |
| Tooth loss due to periodontitis | 0.00 ± 0.00 | 1.67 ± 0.82** |
| Tooth number | 28.00±0.00 | 26.33 ±0.82** |
| PD (mm) | 1.94 ± 0.38 | 3.67 ± 0.90** |
| CAL (mm) | 0.00 ± 0.00 | 3.08 ± 0.87** |
| BOP % | 7.94 ± 1.29 | 92.24 ± 5.10** |
Data are expressed as mean ± SD. Statistical significance is indicated as *p < .05, **p < .01, ***p < .001, and ****p < .0001.
Abbreviations: BMI, body mass index; BOP, bleeding on probing; CAL, clinical attachment loss; PD, probing depth.
Top 10 significantly upregulated and two downregulated circRNAs ranked by fold change in high‐throughput sequencing
| CircRNA | Catalog | Chromosomal location | CircBase ID | Log FC |
|
|---|---|---|---|---|---|
| circPTP4A2 | Exonic | chr1:32381496‐32385259‐ | hsa_circ_0007364 | 5.9157 | .0023 |
| chr22:23101560‐23135351+ | Intergenic | chr22:23101560‐23135351+ | novel | 5.7801 | .0034 |
| circARHGEF28 | Exonic | chr5:73136305‐73136585+ | hsa_circ_0005777 | 5.7015 | .0042 |
| circBARD1 | Exonic | chr2:215617171‐215661841‐ | hsa_circ_0002999 | 5.6773 | .0044 |
| circRASA2 | Exonic | chr3:141231005‐141259451+ | hsa_circ_0067582 | 5.5417 | .0063 |
| circPDK1 | Exonic | chr2:173423436‐173460751+ | novel | 5.4459 | .0080 |
| circCCDC7 | Sense overlapping | chr10:32854486‐32873232+ | hsa_circ_0008679 | 5.4090 | .0087 |
| circNUPL2 | Exonic | chr7:23224689‐23226765+ | hsa_circ_0001683 | 5.3956 | .0090 |
| circANKRD36BP2 | Exonic | chr2:89082251‐89092011+ | novel | 5.2080 | .0139 |
| circMYO9B | Exonic | chr19:17212470‐17213367+ | hsa_circ_0000907 | 5.1745 | .0150 |
| circZBTB8A | Exonic | chr1:33058532‐33059355+ | hsa_circ_0011422 | −5.0565 | .0385 |
| circMAML2 | Exonic | chr11:95825056‐95826681‐ | hsa_circ_0024085 | −5.0384 | .0395 |
FIGURE 2Functional prediction of differentially expressed circRNAs by GO analysis, chromosome location, and online database. (A–C) Gene ontology analysis of selected circRNAs, including cellular component (A), biological process (B), and molecular function (C). Term is the functional description information of GO and count is the number of genes associated with the listed terms. Dot plot shows the enrichment score values of the top most significant enrichment terms. The p value denotes the significance of GO terms enrichment in the genes. The enrichment score was calculated as ‐log10 (p value). (D) Distribution of significantly differentially expressed circRNAs in human chromosomes. (E) Schematic of circRNA‐disease associations prediction by CircDis trained on CircR2Disease v2.0. GCN is used to extract circRNA features and disease features from known circRNA‐disease associations. k‐mer encoding and word embedding help workout feature representation of circRNAs and diseases. Then, circRNA functional similarity, disease similarity, and GIP kernel for circRNAs and diseases are calculated respectively. And GBDT classifier is applied to predict the potential circRNA‐disease associations. GBDT, gradient boosting decision tree; GCN, graph convolutional network; GIP, Gaussian interaction profile. (F) CircRNA‐disease associations predicted by CircR2Disease v2.0. Twelve upregulated circRNAs are predicted to associate with 48 diseases based on CircDis model, with circRNA‐disease association score ranging from 0 to 1 (significant with score >.5; insignificant otherwise)
Function of identified circRNAs in other tissues and disease models
| CircRNA | Disease | Function | Cell and tissue type | Study method | PMID |
|---|---|---|---|---|---|
| hsa_circ_0007364 (circPTP4A2) | Cervical cancer |
Upregulated in cervical cancer Promote cervical cancer progression via miR‐101‐5p/MAT2A axis Promote the proliferation and invasion of cervical cancer cell lines Promote cervical cancer growth in vivo |
Cervical cancer and adjacent nontumor tissues Cervical cancer cell lines (HeLa, CaSki, SiHa, C‐33A, C‐4I, SW756) Normal human cervical epithelial cell line (End1/E6E7) | GEO microarray datasets ( | 33138667 |
| hsa_circ_0007364 (circPTP4A2) | Glioma | Downregulated in glioma | Glioma and normal brain tissues | GEO microarray dataset ( | 31895689 |
| hsa_circ_0007364 (circPTP4A2) | Diabetic kidney disease | Upregulated in human renal proximal tubular epithelial cell line in response to glucose stress | Immortalized human renal proximal tubular epithelial cell line (HK‐2) | Microarray analysis, RT‐qPCR | 32115515 |
| hsa_circ_0005777 (circARHGEF28) | Bladder cancer |
Downregulated in bladder cancer Promote bladder cancer progression through miR‐1305/Tgf‐β2/smad3 pathway targeting EMT Accelerate bladder cancer cells’ progression, including cell viability, proliferation, invasion, migration, and wound healing potential of bladder cancer cell lines |
Bladder cancer and adjacent nontumor tissues Bladder cancer cell lines (5637, UM‐UC‐3) | RNA‐sequencing, RT‐qPCR, FISH, Dual‐luciferase reporter assay, RNA pulldown assay, cell viability assay, cell proliferation assay, cell migration and matrigel invasion assay, wound healing assay, Western blot, tumor subcutaneous mice model | 32019579 |
| hsa_circ_0005777 (circARHGEF28) | Gastric cancer | Downregulated in gastric cancer | Gastric cancer and adjacent nontumor tissues | GEO microarray datasets ( | 31346318 |
| hsa_circ_0005777 (circARHGEF28) | Non‐small cell lung cancer |
Upregulated in non‐small‐cell lung cancer Promote non‐small‐cell lung cancer progression via miR‐671‐5p/FOXM1 axis CircRNA expression associated with tumor size, nodule metastasis, and cancer staging |
Non‐small‐cell lung cancer and adjacent nontumor tissues Immortalized lung epithelial cell line (16HBE) Non‐small‐cell lung cancer cell lines (A549, H460, HCC827) | RT‐qPCR, Western blot, RIP, FISH, RNA pulldown assay, Luciferase reporter assay, cell proliferation assay, cell migration assay | 34291441 |
| hsa_circ_0005777 (circARHGEF28) | Periodontitis | Upregulated in periodontitis | Human gingival tissues | RNA‐sequencing | 31021476 |
| hsa_circ_0067582 (circRASA2) | Gastric cancer |
Downregulated in gastric cancer Associated with gastric cancer patients’ tissue CEA level positively Biomarker for gastric cancer diagnosis |
Gastric cancer and adjacent non‐tumor tissues Healthy gastric mucosa, gastritis mucosa, and gastric intestinal metaplasia tissues | RT‐qPCR | 31328820 |
| hsa_circ_0067582 (circRASA2) | Gastric cancer |
Downregulated in gastric cancer Associated with tumor diameter positively and CA19‐9 level negatively Biomarker for gastric cancer diagnosis and prognosis evaluation | Gastric cancer and adjacent nontumor tissues | RT‐qPCR | 31721300 |
Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; EMT, epithelial‐mesenchymal transition; FISH, florescent in situ hybridization; GEO, Gene Expression Omnibus; RIP, RNA immunoprecipitation.
CircRNA‐disease associations predicted by online CircR2Disease v2.0 database.
Demographic and clinical characteristics of the group of periodontal healthy and the group of periodontitis for RT‐qPCR
| Characteristics | Healthy ( | Periodontitis ( |
|---|---|---|
| Age range (years) | 24–50 | 26–51 |
| Age (years) | 33.46 ± 6.25 | 36.67 ± 7.84 |
| Gender (male/female) | 14/12 | 15/15 |
| BMI (kg/m2) | 20.74 ± 1.04 | 20.46 ± 1.49 |
| Tooth loss due to periodontitis | 0.00 ± 0.00 | 0.40 ± 0.81* |
| Tooth number | 28.00 ± 0.00 | 27.60 ± 0.81* |
| PD (mm) | 2.19 ± 0.57 | 6.53 ± 1.76**** |
| CAL (mm) | 0.00 ± 0.00 | 6.97 ± 2.44**** |
| BOP % | 6.87 ± 1.97 | 76.60 ± 13.34**** |
Data are expressed as mean ± SD. Statistical significance is indicated as *p < .05, **p < .01, ***p < .001, and ****p < .0001.
Abbreviations: BMI, body mass index; BOP, bleeding on probing; CAL, clinical attachment loss; PD, probing depth.
FIGURE 3Identification and validation of the top five upregulated circRNAs expression. (A) Relative expression of five selected circRNAs on high‐throughput sequencing results. (B‐F) Relative expression of circRNAs in gingival tissues from patients with periodontitis (n = 30) and periodontal healthy donors (n = 26) by RT‐qPCR analysis, including circPTP4A2 (B), chr22:23101560‐23135351+ (C), circARHGEF28 (D), circBARD1 (E) and circRASA2 (F). Box and whiskers from Min to Max, showing all points. Significance was expressed as: *p < .05, **p < .01, ***p < .001 and ****p < .0001
FIGURE 4Correlation between relative expression levels of the top five upregulated circRNAs and probing depth. (A) Spearman's correlation analysis was used to assess correlations between circRNA relative expression and probing depth. p < .05 was considered statistically significant. (B) Participants were further divided based on their gender. Four subgroups included male healthy, female healthy, male periodontitis, and female periodontitis. Two‐way ANOVA was used to compare relative expression levels among gender subgroups. (C) Correlations between circRNA relative expression and probing depth were analyzed using Spearman's correlation analysis in male and female participants respectively. Significance was expressed as: *p < .05, **p < .01, ***p < .001, and ****p < .0001
FIGURE 5Expression profiling and GSEA of mRNA. (A) Heatmap displaying differentially expressed mRNAs across gingival tissues from periodontitis patients and periodontal healthy individuals. Gene expression was z‐scored transformed by row. The golden color indicates the upregulated expression and purple color for the downregulated expression (log2 FC >1.8, p < .05). (B) Scatter plot displaying the changes in mRNA expression. The red scatters indicate the upregulated mRNAs, and the blue scatters indicate the downregulated mRNAs with log2 FC >2.0 between the two compared groups. The gray scatters indicate otherwise. (C) Volcano plot showing the expression profiling between the two compared groups. The vertical gray lines refer to a 2.0‐fold change upregulation and downregulation, respectively. The horizontal gray line corresponds to a p value of .05 (−log10 scaled). The red points in the plot represent the significantly upregulated mRNAs, and the blue points represent the significantly downregulated mRNAs. (D) The GSEA of DEGs datasets. The top portion of plots shows the enrichment scores for each gene, and the bottom portion shows the ranked genes. y‐axis: ranking metric, x‐axis: individual ranks for all genes
FIGURE 6Construction of circRNA‐miRNA‐mRNA network and ROC analysis of identified upregulated circRNAs. (A) CircRNA‐miRNA‐mRNA network analysis for the five upregulated circRNAs and differentially expressed mRNAs. (B) Correlations between the five upregulated circRNAs expression and 9 mRNAs expression in high‐throughput sequencing were analyzed by Spearman's correlation analysis. The 9 mRNAs were selected as representatives for nine clusters of circRNA network. p < .05 was considered statistically significant. (C) ROC curves of identified circRNAs in gingival tissues from patients with periodontitis. The largest AUC was demonstrated for chr22:23101560‐23135351+ (0.8667), followed by circARHGEF28 (0.8244), circBARD1 (0.8013), circRASA2 (0.7731), and circPTP4A2 (0.7321). y‐axis indicates the true positive rate of the risk prediction. x‐axis indicates the false‐positive rate of the risk
ROC analysis of identified circRNAs in gingival tissues from patients with periodontitis
| CircRNA | AUC | SEM | 95% CI |
| Sensitivity | Specificity | Cut‐off |
|---|---|---|---|---|---|---|---|
| circPTP4A2 | 0.7321 | 0.0684 | 0.5981, 0.8660 | .0029 | 0.6538 | 0.8000 | 0.01235 |
| chr22:23101560‐23135351+ | 0.8667 | 0.0505 | 0.7677, 0.9656 | <.0001 | 0.6154 | 1.000 | 0.02933 |
| circARHGEF28 | 0.8244 | 0.0547 | 0.7171, 0.9316 | <.0001 | 0.7308 | 0.8333 | 0.01120 |
| circBARD1 | 0.8013 | 0.0591 | 0.6855, 0.9170 | .0001 | 0.7692 | 0.7333 | 0.001554 |
| circRASA2 | 0.7731 | 0.0631 | 0.6493, 0.8968 | .0005 | 0.9231 | 0.5333 | 0.002835 |
Abbreviations: AUC, area under the curve; ROC, receiver‐operating characteristic.
Function of circRNAs in periodontal tissues and cells
| CircRNA | miRNA | Target | Function | Cell/tissue Type | Study method |
|---|---|---|---|---|---|
| hsa_circ_0081572 (circSERPINE1) | miR‐378h |
|
Downregulated in periodontitis Enhance viability, suppress apoptosis, inflammatory response, and oxidative stress to inhibit the progression of periodontitis via miR‐378h/RORA axis |
Human gingival tissues hPDLSCs | RT‐qPCR, CCK‐8 assay, flow cytometry, Western blot; Caspase 3 activity assay; ELISA; ROS level detection; dual‐luciferase reporter assay, RIP, RNA pulldown assay |
| hsa_circ_0085289 (circCTHRC1) | let‐7f‐5p |
|
Downregulated in periodontitis Promote cell viability Suppress proinflammatory cytokines production and apoptosis Alleviate injury of hPDLSCs via let‐7f‐5p/SOCS6 axis in response to LPS |
Human PDL tissues hPDLSCs | RT‐qPCR, ELISA, cell viability assay, Caspase 3 activity assay; flow cytometry, Western blot; dual‐luciferase reporter assay, RNA pulldown assay, RIP |
| hsa_circ_002284 (circMAP3K11) | miR‐511‐3p |
|
Upregulated in periodontitis Promote the cell viability, proliferation, migration and the osteogenic potential Reduce cell apoptosis Promote the proliferation and inhibit the apoptosis of hPDLSCs via miR‐511‐3p/TLR4 axis in vivo |
Human PDL tissues hPDLSCs Periodontitis murine model | Immunohistochemistry assay, target prediction, cell viability assay, cell proliferation assay, cell migration assay, cell apoptosis assay, RT‐qPCR, Western blot, dual‐luciferase reporter assay, TUNEL assay, and Ki‐67 assay in vivo |
| hsa_circ_0003948 (circKDELR2) | miR‐144‐3p |
|
Downregulated in periodontitis Promote cell proliferation and inhibit apoptosis in response to LPS treatment via miR‐144‐3p/NR2F2/PTEN axis |
Human gingival tissues hPDLSCs | RNA‐sequencing, RT‐qPCR, cell proliferation assay, bioinformatic analyses, cell apoptosis assay, dual‐luciferase reporter assay |
| circ‐Amotl1 | miR‐17‐5p |
|
Promote skin wound healing in vivo Promote Stat3 expression and facilitate Stat3 nuclear translocation Promote cell adhesion, migration, proliferation, survival, and wound repair of fibroblasts |
Human gingival fibroblast cell line (CRL‐2014) NIH 3T3 fibroblast cell line Full‐thickness excisional wound murine model | Wound healing experiment in vivo, cell adhesion and migration assays, cell proliferation and survival assays, ChIP, Western blot, RT‐qPCR, RNA pulldown assay, FISH, dual‐luciferase reporter assay |
| circ_0138959 | miR‐527 |
|
Upregulated in periodontitis Suppress cell viability and increase pyroptosis in response to LPS via miR‐527/CASP5 axis Promote the secretion of LDH, IL‐1β, and IL‐18, and increase the protein levels of pyroptosis‐related proteins, including caspase‐1, caspase‐4, and GSDMD‐N |
Human PDL tissues Human gingival fibroblasts (HGFs) | RT‐qPCR, CCK‐8 assay, LDH measurement, ELISA, flow cytometry, Western blot, dual‐luciferase reporter assay, RNA pulldown assay |
| hsa_circ_0003489 (circCDK8) | / | mTOR signaling |
Upregulated in periodontitis Inhibit the osteogenic differentiation of hPDLSCs by triggering autophagy activation and apoptosis through mTOR signaling in a hypoxic microenvironment |
Human PDL tissues hPDLSCs | RT‐qPCR; Western blot; transmission electron microscopy; immunofluorescence analysis; cell apoptosis assay; cell proliferation assay |
| CDR1as | miR‐7 | GDF5/SMAD and p38 MAPK signaling pathway |
Upregulated during osteogenic differentiation Promote osteoblastic differentiation of hPDLSCs via miR‐7/GDF5/SMAD and p38 MAPK signaling pathway in vitro and in vivo |
hPDLSCs Critical‐sized calvarial defect murine model | RNA oligoribonucleotides, ALP staining and activity assay, ARS staining and quantification, RT‐qPCR, Western blot, dual‐luciferase reporter assay, bone formation assay in vivo, micro‐CT, H&E staining, immunofluorescence staining analysis |
| CDR1as | miR‐7 | ERK signal pathway |
Downregulated in periodontitis Regulate the proliferation of hPDLSCs under an LPS‐induced inflammatory condition via miR‐7/ERK signal pathway |
Human PDL tissues hPDLSCs | RT‐qPCR, cell proliferation assay, Western blot |
| CDR1as | miR‐7 |
| Upregulated in response to hnRNPM Maintain stemness of hPDLSCs, including expression levels of stemness‐associated genes (SOX2, OCT4, and Nanog), osteogenic differentiation, adipogenic differentiation and migration via miR‐7/KLF4 axis | hPDLSCs | Osteogenic induction, ALP, and alizarin red staining, Adipogenic induction, Oil Red O staining, RT‐qPCR, cell proliferation assay, cell migration assay, RNA pulldown assay, dual‐luciferase reporter assay |
Abbreviations: CCK‐8, Cell counting kit‐8; ChIP, chromatin immunoprecipitation; ELISA, enzyme‐linked immunosorbent assay; FISH, florescent in situ hybridization; H&E staining, hematoxylin and eosin staining; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; PDL, periodontal ligament; RIP, RNA immunoprecipitation.
Toolbox: how to validate the functions of circRNAs
| Sample preparation | Bioinformatics tools | Clinical indicators | Experimental validation |
|---|---|---|---|
|
Collect clinical features Apply liquid biopsy technology Decrease sampling time
Assess RNA integrity Correct for sample‐to‐sample variations Deplete ribosomal RNA Deplete linear RNAs with RNase R treatment Deplete Poly(A)+ RNA Retain linear and circular RNAs without RNase R treatment
Estimate the false discovery rate Select appropriate thresholds for high‐confidence circRNA detection Test for biochemical artefacts Conduct normalization procedures Standardize tissue sample banks |
DCC* ACFS find_circ
CircBase* CircBank deepBase2.0 CircFunBase CircNet circAtlas
CircR2Disease v2.0* circRNADisease Circ2Traits
starBase v2.0* miRanda* TargetScan* miRBase CircInteractome
Cytoscape* Bioinformatics |
Probing depth (PD) Clinical attachment loss (CAL) Plaque index (PI) Bleeding index (BI) Gingival index (GI) Bleeding on probing (BOP) |
Next‐generation sequencing Microarray Single cell sequencing
RT‐qPCR Sanger sequencing Northern blot Denaturing agarose gel electrophoresis
RIP FISH ChIP Western blot Dual‐luciferase reporter RNA pull‐down Loss and gain of function model
Animal model, e.g., murine model |